share_log

Quanterix to Participate at the Scotiabank Healthcare 1x1 Day

Quanterix to Participate at the Scotiabank Healthcare 1x1 Day

quanterix將參加Scotiabank Healthcare 1x1 Day活動
Quanterix ·  06/17 00:00

BILLERICA, Mass.--(BUSINESS WIRE)--Jun. 17, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer, Masoud Toloue, and Chief Financial Officer, Vandana Sriram, will attend the Scotiabank Healthcare 1x1 Day on June 20, 2024.

美國馬薩諸塞州比勒裏卡--(商業線)--2024年6月17日--Quanterix公司(納斯達克:QTRX)是一家通過超靈敏生物標誌物檢測推動科學發現的公司,今天宣佈,首席執行官Masoud Toloue和首席財務官Vandana Sriram將於2024年6月20日參加Scotiabank Healthcare 1x1 Day。

To learn more about Quanterix, visit www.quanterix.com/company. To learn more about Quanterix's Simoa technology, visit www.quanterix.com/simoa-technology.

要了解更多有關Quanterix的信息,請訪問www.quanterix.com/company要了解有關Quanterix Simoa技術的更多信息,請訪問www.quanterix.com/simoa-technology.

About Quanterix

關於Quanterix

From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.

從探索到診斷,Quanterix的超敏生物標記物檢測通過其無與倫比的靈敏度和適應性推動了突破。該公司的Simoa技術提供了血液、血清或血漿中更早期生物標誌物檢測的黃金標準,能夠量化遠低於檢測限(LoQ)的蛋白質。其行業領先的精密儀器、數字免疫測定技術和CLIA認證的Accelerator實驗室支持了神經學、腫瘤學、免疫學、心臟病學和傳染病領域的疾病認知和管理的研究。Quanterix已成爲科學界近20年的可靠合作伙伴,支持在2900多個同行評審期刊上發表的研究。在位於馬薩諸塞州比勒利卡的該公司網站上查找有關該公司的其他信息https://www.quanterix.com或關注我們的推特和頁面。LinkedIn.

Media Contact:
PAN Communications
Maya Nimnicht
510-334-6273
quanterix@pancomm.com

媒體聯繫人:
PAN通訊
Maya Nimnicht
510-334-6273
quanterix@pancomm.com

Investor Relations Contact:
Quanterix
Francis Pruell
(508)-789-1725
ir@quanterix.com

投資者關係聯繫方式:
Quanterix
Francis Pruell
(508)-789-1725
ir@quanterix.com

Source: Quanterix Corporation

來源:quanterix公司

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論